Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast Cancer February 23, 2023
Tvardi Therapeutics to Participate at the SVB Securities Global Biopharma Conference January 31, 2023